Trending...
- Sea Island Writers Retreat and chromatic black™ Host Three Virtual Writing Workshops
- E3 Forensic Platform Innovates again with Remote Cloud Collection
- InventHelp Inventor Develops New Toss/Target Game (NJD-2447)
PARSIPPANY, N.J.--(BUSINESS WIRE)--Extremity Medical, LLC, a global medical device company focused on the development of innovative implants and instruments for upper and lower extremities, today announced that it has received an award for the Vizient Inc., National Small Joints Category.
The awarded contract includes all Extremity Medical's Upper and Lower Extremity systems, including the innovative KinematX® Total Wrist Arthroplasty system, and the recently launched OMNI® Stable AF (Ankle Fracture) System.
"Extremity Medical is honored to receive a contract from Vizient to offer their members innovative small joint extremity systems," said Matthew Lyons, Extremity Medical Chief Executive Officer, Founder and Chairman of the Board. "Vizient is a top-tier purchasing group that serves more than half the nation's hospitals, so this new contract is a tremendous opportunity for Extremity Medical to improve the lives of more patients nationwide."
More on Jersey Desk
Vizient, Inc., the nation's largest healthcare performance improvement company, serves more than 50% of the nation's acute care providers, which includes 97% of the nation's academic medical centers, and more than 20% of ambulatory care providers. Vizient provides expertise, analytics and advisory services, as well as a contract portfolio that represents more than $130 billion in annual purchasing volume.
About Extremity Medical, LLC
Extremity Medical, LLC, was founded in 2008, and is a privately held medical device company based in Parsippany, NJ. The company is known for creating innovative implants and instruments for upper and lower extremity orthopedic procedures, including fusion and motion preservation. The company is focused on developing solutions for challenging cases that promote better outcomes, especially in patients with poor bone quality.
Contacts
Ira Benson, Vice President of Marketing
973-588-8980
The awarded contract includes all Extremity Medical's Upper and Lower Extremity systems, including the innovative KinematX® Total Wrist Arthroplasty system, and the recently launched OMNI® Stable AF (Ankle Fracture) System.
"Extremity Medical is honored to receive a contract from Vizient to offer their members innovative small joint extremity systems," said Matthew Lyons, Extremity Medical Chief Executive Officer, Founder and Chairman of the Board. "Vizient is a top-tier purchasing group that serves more than half the nation's hospitals, so this new contract is a tremendous opportunity for Extremity Medical to improve the lives of more patients nationwide."
More on Jersey Desk
- ExtensisHR Earns Great Place to Work Certification™
- Unprecedented Stress Levels Reveal Productivity Loss in the Billions; ASCEND Method Enters the Market
- Tech Luminary Adrian Cockcroft Joins OrionX as Partner
- Nomorobo Assists Urgent FCC and Carrier Efforts to Crack Down on Auto Warranty Scam Robocalls
- OPEX® to Exhibit Warehouse Automation Solutions at UK Event for Supply Chain and Logistics Professionals
Vizient, Inc., the nation's largest healthcare performance improvement company, serves more than 50% of the nation's acute care providers, which includes 97% of the nation's academic medical centers, and more than 20% of ambulatory care providers. Vizient provides expertise, analytics and advisory services, as well as a contract portfolio that represents more than $130 billion in annual purchasing volume.
About Extremity Medical, LLC
Extremity Medical, LLC, was founded in 2008, and is a privately held medical device company based in Parsippany, NJ. The company is known for creating innovative implants and instruments for upper and lower extremity orthopedic procedures, including fusion and motion preservation. The company is focused on developing solutions for challenging cases that promote better outcomes, especially in patients with poor bone quality.
Contacts
Ira Benson, Vice President of Marketing
973-588-8980
Filed Under: Business
0 Comments
Latest on Jersey Desk
- HERTHENA-Lung02 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
- Gospel Charting Artist Jeremiah Nedu Is On The Rise With New Single "Your Mercy"
- Peer-Reviewed Study Shows Measurable Impact on Employee Health and Productivity from Employee Assistance Program
- HWS Announces Top 10 Low Cost Vacation Spots
- World's First Walkie-Talkie Bone Conduction Sport Headphones
- U.S. FDA Approves Additional Indication of NUBEQA® (darolutamide) in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Briar Hills Villas Condo Association Names CPM To Manage Suburban Development In West Orange NJ
- Construction Begins on Comprehensive Sedation Dentistry Center in Frederick Maryland
- Kinugawa Onsen Celebrates its 330th Anniversary AND Kawagoe City Celebrates its 100th Anniversary - Both with Fireworks!
- Rook Coffee Brings A Fresh Favorite Back
- Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2022
- VA Center of North County Hosts It's First Annual VANC Fest; an Art, Music and Culinary Experience
- 10 Years in the Making: #LatinaGeeks Celebrates 10th Anniversary with Inaugural Inspirada Awards & Fundraising Gala
- CME Symposium- Fine-Tuning the Management of Patients with #WorseningHeartFailure with Reduced Ejection Fraction
- Alacriti Appoints New Chief Sales Officer and SVP of Faster Payments
- 3i Solutions Announces New Leadership Brings a Customer-Focused Approach
- Cross River Doubles Down on Community Commitment with Spotlight on Financial Literacy
- Perle wins Network Management Product of the Year
- LYNPARZA® (olaparib)Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
- Joseph Federico, Director of NJMET Inc., Announces 2022 STEM Scholarship Recipient